Case number 1:19-cv-02216
Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 17, 2024 | 293 | NOTICE OF SERVICE of (1) Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiff's Second Set of Requests for Production (Nos. 46-84) and; (2) Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiff's Second Set of Interrogatories (Nos. 12-14) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 05/17/2024) (2) |
| May 10, 2024 | 292 | NOTICE OF SERVICE of (1) Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiff and Counterclaim-Defendant's Renewed Requests for Production and; (2) Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiff and Counterclaim-Defendant's Renewed Interrogatories filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 05/10/2024) (2) |
| Apr 29, 2024 | 291 | NOTICE OF SERVICE of Responses and Objections to Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s First Set of Requests for the Production of Documents and Things Relevant to Mylan's Counterclaim Damages (Nos. 1-28) filed by Takeda Pharmaceuticals U.S.A., Inc..(Rahmeier, Thatcher) (Entered: 04/29/2024) (2) |
| Apr 17, 2024 | 290 | NOTICE OF SERVICE of Takeda Pharmaceuticals U.S.A. Inc.'s Second Set of Interrogatories to Defendant (Nos. 12-14); and Takeda Pharmaceuticals U.S.A. Inc.'s Second Set of Requests for the Production of Documents and Things (Nos. 46-84) filed by Takeda Pharmaceuticals U.S.A., Inc..(DiGiovanni, Francis) (Entered: 04/17/2024) (2) |
| Apr 4, 2024 | 289 | REDACTED VERSION of 286 Declaration by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 22, # 2 Exhibit 23, # 3 Exhibit 24, # 4 Exhibit 25)(Rahmeier, Thatcher) (Entered: 04/04/2024) (0) |
| Apr 3, 2024 | 288 | REQUEST for Oral Argument by Mylan Pharmaceuticals Inc. re 274 MOTION for Summary Judgment on Mylan's Counterclaims. (Dorsney, Kenneth) (Entered: 04/03/2024) (1) |
| Apr 1, 2024 | 284 | NOTICE OF SERVICE of Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s First Set of Requests for Production of Documents and Things Relevant to Mylan's Counterclaim Damages (Nos. 1-28) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 04/01/2024) (2) |
| Apr 1, 2024 | 285 | REPLY BRIEF re 274 MOTION for Summary Judgment on Mylan's Counterclaims, 271 MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability filed by Takeda Pharmaceuticals U.S.A., Inc.. (Rahmeier, Thatcher) (Entered: 04/01/2024) (10) |
| Apr 1, 2024 | 286 | [SEALED] DECLARATION re 285 Reply Brief, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 22, # 2 Exhibit 23, # 3 Exhibit 24, # 4 Exhibit 25)(Rahmeier, Thatcher) (Entered: 04/01/2024) (0) |
| Apr 1, 2024 | 287 | REQUEST for Oral Argument by Takeda Pharmaceuticals U.S.A., Inc. re 274 MOTION for Summary Judgment on Mylan's Counterclaims. (Rahmeier, Thatcher) (Entered: 04/01/2024) (1) |
| Mar 22, 2024 | 281 | REPLY BRIEF re 271 MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) (Main Document 281 replaced on 3/25/2024) (nms). (Entered: 03/22/2024) (15) |
| Mar 22, 2024 | 282 | DECLARATION of Sheryl Shapiro Bassin re 281 Reply Brief, by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 3/22/2024 (nms). (Entered: 03/22/2024) (12) |
| Mar 22, 2024 | 283 | REQUEST for Oral Argument by Mylan Pharmaceuticals Inc. re 271 MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability. (Hitch, Cortlan) (Entered: 03/22/2024) (1) |
| Mar 20, 2024 | 280 | REDACTED VERSION of 279 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 14, # 2 Exhibit 15, # 3 Exhibit 16, # 4 Exhibit 17, # 5 Exhibit 18, # 6 Exhibit 19)(DiGiovanni, Francis) (Entered: 03/20/2024) (0) |
| Mar 13, 2024 | 278 | Combined Opening and Answering Brief re 274 MOTION for Summary Judgment on Mylan's Counterclaims, and 271 MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability, filed by Takeda Pharmaceuticals U.S.A., Inc.. Answering Brief/Response due date per Local Rules is 3/27/2024. Reply Brief due date per Local Rules is 3/20/2024. (DiGiovanni, Francis) Modified on 3/13/2024 (nms). (Entered: 03/13/2024) (30) |
| Mar 13, 2024 | 279 | [SEALED] DECLARATION of Porter F. Fleming re 278 Combined Opening and Answering Brief, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 14, # 2 Exhibit 15, # 3 Exhibit 16, # 4 Exhibit 17, # 5 Exhibit 18, # 6 Exhibit 19)(DiGiovanni, Francis) Modified on 3/13/2024 (nms). (Entered: 03/13/2024) (0) |
| Mar 7, 2024 | 277 | ORAL ORDER: The redactions (D.I. 275 ) as supported by the Declaration at D.I. 276 are ACCEPTED. Ordered by Judge Richard G. Andrews on 3/7/2024. (nms) (Entered: 03/07/2024) (0) |
| Mar 6, 2024 | 275 | REDACTED VERSION of 273 Declaration of Sheryl Shapiro Bassin, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 3/6/2024 (nms). (Entered: 03/06/2024) (30) |
| Mar 6, 2024 | 276 | DECLARATION of Preston Imperatore in support of 275 Redacted Document, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 3/6/2024 (nms). (Entered: 03/06/2024) (3) |
| Feb 28, 2024 | 271 | MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 2/28/2024 (nms). (Entered: 02/28/2024) (4) |
| Feb 28, 2024 | 272 | OPENING BRIEF in Support re 271 MOTION for Summary Judgment on Plaintiff and Counterclaim-Defendant Takeda Pharmaceuticals U.S.A. Inc.'s Counterclaims Liability, filed by Mylan Pharmaceuticals Inc.. Answering Brief/Response due date per Local Rules is 3/13/2024. (Dorsney, Kenneth) Modified on 2/28/2024 (nms). (Entered: 02/28/2024) (20) |
| Feb 28, 2024 | 273 | [SEALED] DECLARATION of Sheryl Shapiro Bassin re 272 Opening Brief in Support, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 2/28/2024 (nms). (Entered: 02/28/2024) (0) |
| Feb 28, 2024 | 274 | MOTION for Summary Judgment on Mylan's Counterclaims - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 2/28/2024 (nms). (Entered: 02/28/2024) (3) |
| Feb 20, 2024 | 269 | MOTION for Pro Hac Vice Appearance of Attorney Zachary M. Kravat - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 02/20/2024) (2) |
| Feb 20, 2024 | 270 | Pro Hac Vice Fee - Credit Card Payment received for Zachary M. Kravat. ( re 269 MOTION for Pro Hac Vice Appearance of Attorney Zachary M. Kravat )( Payment of $ 50, receipt number ADEDC-4342064).(Dorsney, Kenneth) (Entered: 02/20/2024) (0) |
| Feb 7, 2024 | 268 | SCHEDULING ORDER: Fact Discovery completed by 8/16/2024. Dispositive Motions due by 2/28/2024. A Pretrial Conference is set for 5/9/2025, at 9:30 AM in Courtroom 6A. A 3-day Jury Trial is set to start 5/27/2025 at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 2/7/2024. (nms) (Entered: 02/07/2024) (5) |
| Feb 6, 2024 | 266 | Letter to Hon. Richard G. Andrews, from Francis DiGiovanni, regarding scheduled for going forward. (Attachments: # 1 Proposed Order)(DiGiovanni, Francis) Modified on 2/6/2024 (nms). (Entered: 02/06/2024) (0) |
| Feb 6, 2024 | 267 | Letter to The Honorable Richard G. Andrews, from Kenneth L. Dorsney, regarding schedule for MPI's counterclaims. (Dorsney, Kenneth) Modified on 2/6/2024 (nms). (Entered: 02/06/2024) (11) |
| Jan 23, 2024 | 265 | MEMORANDUM ORDER: Plaintiff's Motion for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims (D.I. 251 ) is DENIED in part and DISMISSED as moot in part. The parties should meet and confer and within two weeks jointly proposed a schedule for moving forward (see Memorandum Order for further details) Signed by Judge Richard G. Andrews on 1/23/2024. (nms) (Entered: 01/23/2024) (6) |
| Jan 16, 2024 | 264 | ORAL ORDER: The reply brief (D.I. 255 ) is unsealed. How long the generic product was off the market cannot be a secret. The fact that the parties agreed a stipulation would be confidential is also insufficient. The redacted version of the reply brief (D.I. 261) is STRUCK. The redactions to Exhibit C (D.I. 257 ) are allowed. Ordered by Judge Richard G. Andrews on 1/16/2024. (nms) (Entered: 01/16/2024) (0) |
| Jan 5, 2024 | 262 | REDACTED VERSION of 257 Sealed Exhibit C, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 1/5/2024 (nms). (Entered: 01/05/2024) (6) |
| Jan 5, 2024 | 263 | DECLARATION of Preston Imperatore in support of Redactions (D.I. 261 and 262 ), by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 1/5/2024 (nms). Modified on 1/5/2024 (nms). (Entered: 01/05/2024) (2) |
| Dec 26, 2023 | 260 | REQUEST for Oral Argument regarding Motion for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims (D.I. 259 ), by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 1/2/2024 (nms). (Entered: 12/26/2023) (1) |
| Dec 22, 2023 | 258 | NOTICE requesting Clerk to remove Elham Firouzi Steiner as co-counsel.. (Dorsney, Kenneth) (Entered: 12/22/2023) (1) |
| Dec 22, 2023 | 259 | STIPULATION and Proposed Order Extending Time to file redacted version of Reply Brief and related exhibit to January 5, 2024 - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 12/22/2023 (nms). (Entered: 12/22/2023) (2) |
| Dec 19, 2023 | 255 | REPLY BRIEF re 251 MOTION for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims, filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Certificate of Service)(DiGiovanni, Francis) Modified on 1/16/2024 (nms). (Entered: 12/19/2023) (0) |
| Dec 19, 2023 | 256 | DECLARATION of Porter F. Fleming re 255 Reply Brief, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 12/19/2023 (nms). (Entered: 12/19/2023) (1) |
| Dec 19, 2023 | 257 | [SEALED] Exhibit C to 256 Declaration of Porter F. Fleming, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Certificate of Service)(DiGiovanni, Francis) Modified on 12/19/2023 (nms). (Entered: 12/19/2023) (0) |
| Dec 12, 2023 | 254 | ANSWERING BRIEF in Opposition re 251 MOTION for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims filed by Mylan Pharmaceuticals Inc..Reply Brief due date per Local Rules is 12/19/2023. (Hitch, Cortlan) (Entered: 12/12/2023) (22) |
| Nov 28, 2023 | 251 | MOTION for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 11/28/2023 (nms). (Entered: 11/28/2023) (4) |
| Nov 28, 2023 | 252 | OPENING BRIEF in Support re 251 MOTION for Entry of Judgment under Rule 54(b), filed by Takeda Pharmaceuticals U.S.A., Inc..Answering Brief/Response due date per Local Rules is 12/12/2023. (DiGiovanni, Francis) Modified on 11/28/2023 (nms). (Entered: 11/28/2023) (18) |
| Nov 28, 2023 | 253 | DECLARATION of Porter F. Fleming re 251 MOTION for a Rule 54(b) Final Judgment as to Takeda's Claims and to Stay Mylan's Counterclaims, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(DiGiovanni, Francis) Modified on 11/28/2023 (nms). (Entered: 11/28/2023) (0) |
| Nov 17, 2023 | 250 | ORAL ORDER: The Court has reviewed the recent letters. (D.I. 248 ; D.I. 249 ). Takeda should file a Rule 54(b) motion accompanied by a brief. The brief may, to the extent Takeda chooses, borrow heavily from its letter. The briefing schedule, in the absence of agreement of the parties, should follow the Local Rules. The Court will not set any further schedule until the Rule 54(b) motion is resolved. Ordered by Judge Richard G. Andrews on 11/17/2023. (nms) (Entered: 11/17/2023) (0) |
| Nov 1, 2023 | 248 | Letter to Hon. Richard G. Andrews, from Francis DiGiovanni, regarding response to Order (D.I. 245 ). (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) Modified on 11/1/2023 (nms). (Entered: 11/01/2023) (0) |
| Nov 1, 2023 | 249 | Letter to The Honorable Richard G. Andrews, from Kenneth L. Dorsney, regarding remainder of case. (Dorsney, Kenneth) Modified on 11/1/2023 (nms). (Entered: 11/01/2023) (7) |
| Oct 16, 2023 | 247 | STIPULATION and Proposed Order for Extension of Time to submit a jointly proposed order resolving the remainder of the case to November 1, 2023 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Rahmeier, Thatcher) Modified on 10/16/2023 (nms). (Entered: 10/16/2023) (2) |
| Oct 3, 2023 | 246 | STIPULATION and Proposed Order for Extension of Time to submit a jointly proposed order resolving the remainder of the case to October 18, 2023 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Rahmeier, Thatcher) Modified on 10/3/2023 (nms). (Entered: 10/03/2023) (2) |
| Sep 27, 2023 | 244 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 9/27/2023. (nms) (Entered: 09/27/2023) (15) |
| Sep 27, 2023 | 245 | ORDER: Defendant Mylan's Motion for Summary Judgment and to Exclude Expert Testimony (D.I. 216 ) is GRANTED as to the motion for summary judgment and is DISMISSED as MOOT as to the Motion to Exclude Expert Testimony. Judgment is GRANTED in favor of Defendant Mylan on Count I-Breach of the License Agreement. The Parties should within seven days submit a jointly proposed order resolving the remainder of the case. Signed by Judge Richard G. Andrews on 9/27/2023. (nms) (Entered: 09/27/2023) (1) |
| Sep 24, 2023 | 243 | Official Transcript of Oral Argument held on 8/15/23 before Judge Richard G. Andrews. Court Reporter: Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/16/2023. Redacted Transcript Deadline set for 10/25/2023. Release of Transcript Restriction set for 12/26/2023. (Triozzi, Heather) (Entered: 09/24/2023) (35) |
| Aug 23, 2023 | 242 | Official Transcript of Oral Argument held on 8/15/23 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/13/2023. Redacted Transcript Deadline set for 9/25/2023. Release of Transcript Restriction set for 11/21/2023. (Triozzi, Heather) (Entered: 08/23/2023) (41) |
| Aug 10, 2023 | 240 | Amended Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (3) |
| Aug 10, 2023 | 241 | SO ORDERED Granting 240 Amended Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 8/10/2023. (nms) (nms). (Entered: 08/10/2023) (3) |
| Aug 4, 2023 | 239 | ORAL ORDER: The hearing on the Motion for Summary Judgment (D.I. 216 ) is now rescheduled for 8/15/2023, at 9:00 AM in Courtroom 6A. The parties will be limited to 15 minutes per side.. Ordered by Judge Richard G. Andrews on 8/4/2023. (nms) (Entered: 08/04/2023) (0) |
| Aug 3, 2023 | 238 | ORAL ORDER: Due to an unforeseen scheduling conflict the hearing scheduled for 8/7/2023, is CANCELED. The hearing will be rescheduled for a date to be determined. Ordered by Judge Richard G. Andrews on 8/3/2023. (nms) (Entered: 08/03/2023) (0) |
| Jul 21, 2023 | 236 | Amended Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 7/21/2023 (nms). (Entered: 07/21/2023) (3) |
| Jul 21, 2023 | 237 | SO ORDERED Granting 236 Amended Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 7/21/2023. (nms) (Entered: 07/21/2023) (3) |
| Jul 19, 2023 | 235 | NOTICE of Withdrawal of Alexander Weiner, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 7/19/2023 (nms). (Entered: 07/19/2023) (1) |
| Jul 18, 2023 | 234 | ORAL ORDER: The hearing on the Motion for Summary Judgment (D.I. 216 ) is now rescheduled for 8/7/2023, at 9:00 AM in Courtroom 6A. The parties will be limited to 15 minutes per side. Ordered by Judge Richard G. Andrews on 7/18/2023. (nms) (Entered: 07/18/2023) (0) |
| Jul 17, 2023 | 231 | Joint Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 7/17/2023 (nms). (Entered: 07/17/2023) (3) |
| Jul 17, 2023 | 232 | SO ORDERED Granting 231 Joint Motion for Exemption of Persons from the May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 7/17/2023. (nms) (nms). (Entered: 07/17/2023) (3) |
| Jul 17, 2023 | 233 | ORAL ORDER: Due to an unforeseen scheduling conflict the hearing scheduled for 7/18/2023, is CANCELED. The hearing on the motion will be rescheduled for a date to be determined. Ordered by Judge Richard G. Andrews on 7/17/2023. (nms) (Entered: 07/17/2023) (0) |
| Jul 10, 2023 | 230 | ORAL ORDER: A hearing on the Motion for Summary Judgment (D.I. 216 ) is now set for 7/18/2023, at 2:00 PM in Courtroom 6A. The parties will be limited to 15 minutes per side. Ordered by Judge Richard G. Andrews on 7/10/2023. (nms) (Entered: 07/10/2023) (0) |
| Jul 5, 2022 | 229 | REQUEST for Oral Argument by Takeda Pharmaceuticals U.S.A., Inc. re 216 MOTION for Summary Judgment and to Exclude Expert Testimony. (DiGiovanni, Francis) (Entered: 07/05/2022) (1) |
| Jun 30, 2022 | 226 | REPLY BRIEF re 216 MOTION for Summary Judgment and to Exclude Expert Testimony filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) (Main Document 226 replaced on 7/7/2022) (lak). (Entered: 06/30/2022) (20) |
| Jun 30, 2022 | 227 | DECLARATION re 226 Reply Brief, by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) Modified on 7/1/2022 (nms). (Entered: 06/30/2022) (30) |
| Jun 30, 2022 | 228 | Letter to The Honorable Richard G. Andrews, from Cortlan S. Hitch, regarding request for oral argument on Mylan's Combined Motion for Summary Judgment and to Exclude Expert Testimony. (Hitch, Cortlan) Modified on 7/1/2022 (nms). (Entered: 06/30/2022) (1) |
| Jun 17, 2022 | 224 | REDACTED VERSION of 222 Answering Brief in Opposition by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 06/17/2022) (30) |
| Jun 17, 2022 | 225 | REDACTED VERSION of 223 Declaration of Francis DiGiovanni, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibits 48-66)(DiGiovanni, Francis) Modified on 6/17/2022 (nms). (Entered: 06/17/2022) (Main Document) (5) |
| Jun 17, 2022 | 225 | REDACTED VERSION of 223 Declaration of Francis DiGiovanni, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibits 48-66)(DiGiovanni, Francis) Modified on 6/17/2022 (nms). (Entered: 06/17/2022) (Exhibit Exhibits 48-66) (30) |
| Jun 10, 2022 | 222 | [SEALED] ANSWERING BRIEF in Opposition re 216 MOTION for Summary Judgment and to Exclude Expert Testimony filed by Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 6/17/2022. (DiGiovanni, Francis) (Entered: 06/10/2022) (0) |
| Jun 10, 2022 | 223 | [SEALED] DECLARATION of Francis DiGiovanni re 222 Answering Brief in Opposition, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibits 48-66)(DiGiovanni, Francis) Modified on 6/13/2022 (nms). (Entered: 06/10/2022) (0) |
| May 13, 2022 | 219 | REDACTED VERSION of 217 Opening Brief in Support, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 5/16/2022 (nms). (Entered: 05/13/2022) (30) |
| May 13, 2022 | 220 | REDACTED VERSION of 218 Declaration of Sheryl Shapiro Bassin, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 5/16/2022 (nms). (Entered: 05/13/2022) (30) |
| May 13, 2022 | 221 | DECLARATION of Preston Imperatore in support of 219 Redacted Document, 220 Redacted Document, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 5/16/2022 (nms). (Entered: 05/13/2022) (3) |
| May 6, 2022 | 216 | MOTION for Summary Judgment and to Exclude Expert Testimony - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 5/9/2022 (nms). (Entered: 05/06/2022) (5) |
| May 6, 2022 | 217 | [SEALED] OPENING BRIEF in Support re 216 MOTION for Summary Judgment and to Exclude Expert Testimony filed by Mylan Pharmaceuticals Inc..Answering Brief/Response due date per Local Rules is 5/20/2022. (Dorsney, Kenneth) Modified on 5/9/2022 (nms). (Entered: 05/06/2022) (0) |
| May 6, 2022 | 218 | [SEALED] DECLARATION of Sheryl Shapiro Bassin re 217 Opening Brief in Support, by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 1-33, # 2 Exhibits 34-47)(Dorsney, Kenneth) Modified on 5/9/2022 (nms). (Entered: 05/06/2022) (0) |
| Apr 29, 2022 | 215 | SO ORDERED Granting 214 Joint Stipulation Concerning Page Limits for Case Dispositive and Daubert Motions. Signed by Judge Richard G. Andrews on 4/29/2022. (nms) (Entered: 04/29/2022) (3) |
| Apr 28, 2022 | 214 | Joint STIPULATION Concerning Page Limits for Case Dispositive and Daubert Motions by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 04/28/2022) (3) |
| Mar 23, 2022 | 213 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Notice of Deposition of Peter H. Rheinstein filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 03/23/2022) (2) |
| Mar 22, 2022 | 212 | MOTION for Pro Hac Vice Appearance of Attorney Elham Firouzi Steiner - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 03/22/2022) (2) |
| Feb 28, 2022 | 211 | NOTICE OF SERVICE of Mylan's Rebuttal Expert Report of Kurt R. Karst, Esq. filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 02/28/2022) (2) |
| Jan 18, 2022 | 210 | NOTICE of Service of Opening Expert Report of Dr. Peter Rheinstein and Exhibits Thereto by Takeda Pharmaceuticals U.S.A., Inc. (DiGiovanni, Francis) (Entered: 01/18/2022) (2) |
| Nov 22, 2021 | 209 | SO ORDERED Granting 208 Joint Stipulation for Second Amended Scheduling Order (*Reset Deadlines: Dispositive Motions due by 5/6/2022) (see Order for further details). Signed by Judge Richard G. Andrews on 11/22/2021. (nms) (Entered: 11/22/2021) (3) |
| Nov 18, 2021 | 208 | Joint Stipulation for Second Amended Scheduling Order, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 11/19/2021 (nms). (Entered: 11/18/2021) (3) |
| Nov 12, 2021 | 204 | Letter to The Honorable Richard G. Andrews, from Kenneth L. Dorsney, regarding deposition dispute. (Dorsney, Kenneth) Modified on 11/12/2021 (nms). (Entered: 11/12/2021) (3) |
| Nov 12, 2021 | 205 | [SEALED] Letter to Hon. Richard G. Andrews from Francis DiGiovanni. (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) (Entered: 11/12/2021) (0) |
| Nov 12, 2021 | 206 | REDACTED VERSION of 205 Letter by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) (Entered: 11/12/2021) (Main Document) (3) |
| Nov 12, 2021 | 207 | ORAL ORDER: Having reviewed the letters (D.I. 204 , 205 ), and considering that the objection to an in-person deposition appears to be based principally on the general reluctance of Mylans counsel to fly across the country, but also noting that Mylans law firm has about 250 lawyers in the Bay Area, one of whom entered an appearance in this case, and that the deponent has raised no objection based on the pandemic, I do not think there is any good reason not to conduct the deposition in person in the Bay Area. Takedas request for an in-person deposition is granted. Ordered by Judge Richard G. Andrews on 11/12/2021. (nms) (Entered: 11/12/2021) (0) |
| Nov 12, 2021 | 206 | REDACTED VERSION of 205 Letter by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) (Entered: 11/12/2021) (Exhibit A) (3) |
| Oct 25, 2021 | 202 | NOTICE OF SERVICE of Notices of deposition for Heather Takahashi, Jason Maxwell and Jeffrey Weinberger filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 10/25/2021) (2) |
| Oct 25, 2021 | 203 | NOTICE of Service of Notices of Deposition to Preston Imperatore, Sami Sedghani, Nicole Stafford by Takeda Pharmaceuticals U.S.A., Inc. (DiGiovanni, Francis) (Entered: 10/25/2021) (2) |
| Oct 11, 2021 | 201 | NOTICE of Service of Plaintiff Takeda Pharmaceuticals U.S.A., Inc.s Amended Initial Disclosures Under Fed. R. Civ. P. 26(a)(1) and Plaintiff Takeda Pharmaceuticals U.S.A., Inc.s Amended Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery by Takeda Pharmaceuticals U.S.A., Inc. (DiGiovanni, Francis) (Entered: 10/11/2021) (2) |
| Sep 10, 2021 | 200 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Amended Responses and Objections to Plaintiffs' Interrogatory No. 3 filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 09/10/2021) (2) |
| Aug 23, 2021 | 199 | NOTICE requesting Clerk to remove Mary Zou as co-counsel.. (Dorsney, Kenneth) (Entered: 08/23/2021) (1) |
| Jul 8, 2021 | 197 | Joint Stipulation Regarding Amended Scheduling Order, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 7/8/2021 (nms). (Entered: 07/08/2021) (4) |
| Jul 8, 2021 | 198 | SO ORDERED Granting 197 Joint Stipulation Regarding Amended Scheduling Order (see Order for further details). Signed by Judge Richard G. Andrews on 7/8/2021. (nms) (Entered: 07/08/2021) (4) |
| Jun 22, 2021 | 195 | REDACTED VERSION of 192 Letter, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 6/22/2021 (nms). (Entered: 06/22/2021) (30) |
| Jun 21, 2021 | 193 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Amended Rule 26(a)(1) Initial Disclosures filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 06/21/2021) (2) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Main Document) (4) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit A) (5) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit B) (5) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit C) (13) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit D) (6) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit E) (7) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit F) (30) |
| Jun 21, 2021 | 194 | REDACTED VERSION of 191 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/21/2021) (Exhibit G) (2) |
| Jun 15, 2021 | 192 | [SEALED] Letter to The Honorable Richard G. Andrews, from Kenneth L. Dorsney, responding Mylan's discovery dispute letter. (Dorsney, Kenneth) Modified on 6/16/2021 (nms). (Entered: 06/15/2021) (0) |
| Jun 11, 2021 | 191 | [SEALED] Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Discovery Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(DiGiovanni, Francis) (Entered: 06/11/2021) (0) |
| Jun 8, 2021 | 190 | ORAL ORDER: The parties have advised that a dispute has arisen requiring judicial attention. The Court will hold a discovery conference on 6/22/2021, at 10:00 AM. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. The hearing will be held using Teams. A joint email with the email addresses for all those participating in the conference shall be due to the Court's Case Manager by 4:00 PM on 6/15/2021. Ordered by Judge Richard G. Andrews on 6/8/2021. (nms) (Entered: 06/08/2021) (0) |
| Jun 1, 2021 | 189 | NOTICE OF SERVICE of Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s Second Amended Responses and Objections to Plaintiff and Counterclaim-Defendant First Set of Requests for Admission (Nos. 1-3) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 06/01/2021) (2) |
| May 25, 2021 | 188 | NOTICE OF SERVICE of Defendant and Counterclaim-Plaintiff Mylan Pharmaceuticals Inc.'s Amended Responses and Objections to Plaintiff and Counterclaim-Defendant First Set of Requests for Admission (Nos. 1-3) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 05/25/2021) (2) |
| May 6, 2021 | 187 | MOTION for Pro Hac Vice Appearance of Attorney Mary Zou - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 05/06/2021) (2) |
| Apr 8, 2021 | 186 | NOTICE of Service of Discovery Responses by Takeda Pharmaceuticals U.S.A., Inc. (Rahmeier, Thatcher) (Entered: 04/08/2021) (2) |
| Mar 18, 2021 | 185 | MOTION for Pro Hac Vice Appearance of Attorney Cassie Leigh Black and Attorney Alexander Weiner - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 03/18/2021) (3) |
| Feb 24, 2021 | 184 | NOTICE OF SERVICE of (1) Mylan Pharmaceuticals Inc.'s First Set of Interrogatories to Takeda (Nos. 1-18) and; (2) Mylan Pharmaceuticals Inc.'s First Set of Requests for the Production of Documents and Things to Takeda (Nos. 1-54) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 02/24/2021) (2) |
| Feb 16, 2021 | 183 | PROTECTIVE ORDER. Signed by Judge Richard G. Andrews on 2/16/2021. (nms) (Entered: 02/16/2021) (21) |
| Feb 11, 2021 | 181 | Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Proposed Protective Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) (Entered: 02/11/2021) (Main Document) (4) |
| Feb 11, 2021 | 182 | Letter to The Honorable Richard G. Andrews from Cortlan S. Hitch regarding Protective Order issue. (Hitch, Cortlan) (Entered: 02/11/2021) (12) |
| Feb 11, 2021 | 181 | Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Proposed Protective Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) (Entered: 02/11/2021) (Exhibit A) (22) |
| Feb 11, 2021 | 181 | Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Proposed Protective Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) (Entered: 02/11/2021) (Exhibit B) (7) |
| Feb 11, 2021 | 181 | Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Proposed Protective Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) (Entered: 02/11/2021) (Exhibit C) (6) |
| Feb 11, 2021 | 181 | Letter to The Honorable Richard G. Andrews from Francis DiGiovanni regarding Proposed Protective Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) (Entered: 02/11/2021) (Exhibit D) (8) |
| Feb 4, 2021 | 179 | NOTICE OF SERVICE of (1) Mylan's responses to Plaintiff's First Set of Interrogatories (Nos. 1-11); (2) Mylan's responses to Plaintiff's First Set of Requests for Production (Nos. 1-45); and (3) Mylan's responses to Plaintiff's First Set of Requests for Admission (Nos. 1-3) filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 02/04/2021) (2) |
| Feb 4, 2021 | 180 | NOTICE of Service of (1) Initial Disclosures Under Fed. R. Civ. P. 26(a)(1); and (2) Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 2/5/2021 (nms). (Entered: 02/04/2021) (2) |
| Feb 3, 2021 | 178 | NOTICE OF SERVICE of for (1) Mylan Pharmaceuticals Inc.'s Rule 26(a) Initial Disclosures and; (2) Mylan Pharmaceuticals Inc.'s Paragraph 3 Initial Disclosures filed by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 02/03/2021) (2) |
| Jan 29, 2021 | 177 | STIPULATION TO EXTEND TIME for Rule 26(a)(1) and Paragraph 3 disclosures to February 3, 2021 - filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) (Entered: 01/29/2021) (2) |
| Jan 22, 2021 | 176 | STIPULATION and Proposed Order for Extension of Application Date for Protective Order, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 1/22/2021 (nms). (Entered: 01/22/2021) (2) |
| Jan 14, 2021 | 175 | STIPULATION and Proposed Order for Extension of Application Date for Protective Order - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Rahmeier, Thatcher) Modified on 1/15/2021 (nms). (Entered: 01/14/2021) (2) |
| Dec 28, 2020 | 174 | ORDER: Plaintiff shall provide all licenses and/or settlement agreements concerning the Patents in Suit to Defendant no later than seven (7) days after entry of the Protective Order in this case. Signed by Judge Richard G. Andrews on 12/28/2020. (nms) (Entered: 12/28/2020) (1) |
| Dec 23, 2020 | 173 | Letter to The Honorable Richard G. Andrews, from Francis DiGiovanni, regarding order regarding production of settlement agreements and licenses. (Attachments: # 1 Proposed Order)(DiGiovanni, Francis) Modified on 12/23/2020 (nms). (Entered: 12/23/2020) (Main Document) (1) |
| Dec 23, 2020 | 173 | Letter to The Honorable Richard G. Andrews, from Francis DiGiovanni, regarding order regarding production of settlement agreements and licenses. (Attachments: # 1 Proposed Order)(DiGiovanni, Francis) Modified on 12/23/2020 (nms). (Entered: 12/23/2020) (Proposed Order) (1) |
| Dec 22, 2020 | 171 | ANSWER to 164 Answer to Complaint, and Counterclaim, by Takeda Pharmaceuticals U.S.A., Inc..(DiGiovanni, Francis) Modified on 12/22/2020 (nms). (Entered: 12/22/2020) (14) |
| Dec 22, 2020 | 172 | NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories to Defendant (Nos. 1-11); Plaintiff's First Request for Production of Documents and Things (Nos. 1-45) and Plaintiff's First Set of Requests for Admissions (Nos. 1-3) filed by Takeda Pharmaceuticals U.S.A., Inc..(DiGiovanni, Francis) (Entered: 12/22/2020) (2) |
| Dec 14, 2020 | 166 | PROPOSED Scheduling Order, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 12/14/2020 (nms). (Entered: 12/14/2020) (9) |
| Dec 14, 2020 | 167 | Letter to The Honorable Richard G. Andrews, from Francis DiGiovanni regarding Dial-in-Information for 16(b) Telephone Conference. (DiGiovanni, Francis) Modified on 12/14/2020 (nms). (Entered: 12/14/2020) (1) |
| Dec 14, 2020 | 168 | SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 5/14/2021. Amended Pleadings due by 5/14/2021. Fact Discovery completed by 12/10/2021. Dispositive Motions due by 7/15/2022. A Pretrial Conference is set for 12/15/2022, at 9:00 AM in Courtroom 6A. A 5 day Jury Trial is set to start 1/23/2023, at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 12/14/2020. (nms) (Entered: 12/14/2020) (9) |
| Dec 14, 2020 | 169 | ORAL ORDER: The Rule 16(b) Conference set for 12/16/2020, is CANCELED. Ordered by Judge Richard G. Andrews on 12/14/2020. (nms) (Entered: 12/14/2020) (0) |
| Dec 14, 2020 | 170 | ORAL ORDER: This matter has been referred to Chief Magistrate Judge Mary Pat Thynge for ADR. Counsel are to advise on or before 1/11/21 by a JOINT EMAIL to Judge Thynge, with a copy to her Judicial Administrator, Ms. Kennedy, their clients interest in mediation and the timing when mediation is preferred with a very brief explanation why. When referencing the timing for mediation, counsel rely on certain events in the scheduling order, for example, before claim construction briefing, after the close of discovery, before expert reports and the like, they are to include the date(s) on when such event(s) occur. Ordered by Chief Magistrate Judge Mary Pat Thynge on 12/14/20. (cak) (Entered: 12/14/2020) (0) |
| Dec 4, 2020 | 165 | Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 12/16/2020, at 10:00 AM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 12/4/2020. (nms) (Entered: 12/04/2020) (1) |
| Dec 1, 2020 | 164 | ANSWER to 2 Complaint with Jury Demand, and COUNTERCLAIMS against Takeda Pharmaceuticals U.S.A., Inc., by Mylan Pharmaceuticals Inc..(Dorsney, Kenneth) Modified on 12/2/2020 (nms). (Entered: 12/01/2020) (30) |
| Nov 25, 2020 | 163 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Hitch, Cortlan) (Entered: 11/25/2020) (2) |
| Nov 17, 2020 | 162 | ORAL ORDER: The motion for reconsideration (D.I. 156 ) is DENIED. While I understand the argument that the Court of Appeals finally decided a controlling question of law adversely to Plaintiff, I do not think that the Court did. First, the Court multiple times cited the preliminary injunction standard of likelihood of success. Second, in the passage that I consider to be the most succinct explanation of the Courts decision, the Court held that the final judgment in the West-Ward Litigation likely triggers Section 1.2(d) of the License Agreement. 967 F.3d at 1345 (emphasis added). Third, the Court addressed irreparable harm, which, under Defendants theory, would have been superfluous. Fourth, for the reasons stated by Judge Jordan in Association of New Jersey Rifle & Pistol Clubs Inc. v. Attorney General New Jersey, 974 F.3d 237, 245 n.6 (3d Cir. 2020), I think any ambiguity in the finality of the Court of Appeals holding on an issue that it was not required to decide should be resolved in favor of this Court allowing the parties to create a fully-developed record before the merits are presented to the Court of Appeals. Ordered by Judge Richard G. Andrews on 11/17/2020. (nms) (Entered: 11/17/2020) (0) |
| Sep 29, 2020 | 161 | ANSWERING BRIEF in Opposition re 156 MOTION for Reconsideration filed by Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 10/6/2020. (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) (Entered: 09/29/2020) (Main Document) (15) |
| Sep 29, 2020 | 161 | ANSWERING BRIEF in Opposition re 156 MOTION for Reconsideration filed by Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 10/6/2020. (Attachments: # 1 Exhibit A)(DiGiovanni, Francis) (Entered: 09/29/2020) (Exhibit A) (4) |
| Sep 21, 2020 | 160 | REQUEST for Oral Argument by Mylan Pharmaceuticals Inc. re 156 MOTION for Reconsideration . (Dorsney, Kenneth) (Entered: 09/21/2020) (2) |
| Sep 17, 2020 | 159 | SO ORDERED, re 158 STIPULATION TO EXTEND TIME Respond to Complaint to 14 days after Ruling on Motion for Reconsideration. Signed by Judge Richard G. Andrews on 9/17/2020. (nms) (Entered: 09/17/2020) (2) |
| Sep 16, 2020 | 156 | MOTION for Reconsideration - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 09/16/2020) (17) |
| Sep 16, 2020 | 157 | DECLARATION re 156 MOTION for Reconsideration by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 09/16/2020) (7) |
| Sep 16, 2020 | 158 | STIPULATION TO EXTEND TIME Respond to Complaint to 14 days after Ruling on Motion for Reconsideration - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 09/16/2020) (2) |
| Sep 10, 2020 | 155 | MOTION for Pro Hac Vice Appearance of Attorney Jonathan Herstoff and Camille Y. Turner - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 09/10/2020) (3) |
| Sep 9, 2020 | 154 | ORAL ORDER: The motion to dismiss (D.I. 71 ) is DENIED. While an appellate ruling on an appeal from the denial of a preliminary injunction could resolve the underlying legal issues, see Association of New Jersey Rifle & Pistol Clubs Inc. v. Attorney General New Jersey, 2020 WL 5200683 at *5-6 (3d Cir. Sept. 1, 2020), my reading of the Court of Appeals' opinion is that it resolved the appeal under the preliminary injunction standard and therefore did not establish the law of the case such that the motion to dismiss should be granted. Nor am I convinced by the briefing (D.I. 76, 142, 150, 151-1) that I can decide now that the underlying agreement is unambiguous. The motion for leave to participate as an amicus curiae (D.I. 111) is moot and is therefore DISMISSED. The motion to file a surreply (D.I. 151) is GRANTED. Ordered by Judge Richard G. Andrews on 9/9/2020. (nms) (Entered: 09/09/2020) (0) |
| Sep 8, 2020 | 153 | MANDATE of USCA as to 115 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc., 118 Notice of Appeal (Federal Circuit) filed by Takeda Pharmaceuticals U.S.A., Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 09/08/2020) (Main Document) (1) |
| Sep 8, 2020 | 153 | MANDATE of USCA as to 115 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc., 118 Notice of Appeal (Federal Circuit) filed by Takeda Pharmaceuticals U.S.A., Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 09/08/2020) (Opinion) (24) |
| Sep 8, 2020 | 153 | MANDATE of USCA as to 115 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc., 118 Notice of Appeal (Federal Circuit) filed by Takeda Pharmaceuticals U.S.A., Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 09/08/2020) (Judgment) (1) |
| Aug 28, 2020 | 152 | REDACTED VERSION of 150 Reply Brief, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 8/28/2020 (nms). (Entered: 08/28/2020) (16) |
| Aug 26, 2020 | 151 | MOTION to File a Surreply Brief in Response to Defendant's Motion to Dismiss - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1, # 3 Proposed Order)(DiGiovanni, Francis) Modified on 8/26/2020 (nms). (Entered: 08/26/2020) (Main Document) (3) |
| Aug 26, 2020 | 151 | MOTION to File a Surreply Brief in Response to Defendant's Motion to Dismiss - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1, # 3 Proposed Order)(DiGiovanni, Francis) Modified on 8/26/2020 (nms). (Entered: 08/26/2020) (Exhibit A) (10) |
| Aug 26, 2020 | 151 | MOTION to File a Surreply Brief in Response to Defendant's Motion to Dismiss - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1, # 3 Proposed Order)(DiGiovanni, Francis) Modified on 8/26/2020 (nms). (Entered: 08/26/2020) (Exhibit 1) (12) |
| Aug 26, 2020 | 151 | MOTION to File a Surreply Brief in Response to Defendant's Motion to Dismiss - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1, # 3 Proposed Order)(DiGiovanni, Francis) Modified on 8/26/2020 (nms). (Entered: 08/26/2020) (Proposed Order) (1) |
| Aug 25, 2020 | 148 | REQUEST for Oral Argument by Takeda Pharmaceuticals U.S.A., Inc. re 71 MOTION to Dismiss. (Rahmeier, Thatcher) (Entered: 08/25/2020) (1) |
| Aug 25, 2020 | 149 | ORDER Granting 146 Unopposed MOTION to File Under Seal Certain Portions of Reply Brief. Signed by Judge Richard G. Andrews on 8/25/2020. (nms) (Entered: 08/25/2020) (1) |
| Aug 25, 2020 | 150 | [SEALED] REPLY BRIEF re 71 MOTION to Dismiss, filed by Mylan Pharmaceuticals Inc.. (nms) (Entered: 08/25/2020) (0) |
| Aug 24, 2020 | 146 | Unopposed MOTION to File Under Seal Certain Portions of Reply Brief - filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Dorsney, Kenneth) Modified on 8/25/2020 (nms). (Entered: 08/24/2020) (Main Document) (3) |
| Aug 24, 2020 | 147 | [SEALED] EXHIBITS re 146 Unopposed MOTION to File Under Seal Certain Portions of Reply Brief, by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dorsney, Kenneth) Modified on 8/25/2020 (nms). (Entered: 08/24/2020) (0) |
| Aug 24, 2020 | 146 | Unopposed MOTION to File Under Seal Certain Portions of Reply Brief - filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Dorsney, Kenneth) Modified on 8/25/2020 (nms). (Entered: 08/24/2020) (Text of Proposed Order) (1) |
| Jul 31, 2020 | 145 | NOTICE requesting Clerk to remove Shyamkrishna Palaiyanur as co-counsel.. (Dorsney, Kenneth) (Entered: 07/31/2020) (1) |
| Jul 17, 2020 | 144 | STIPULATION for Extension of Time - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 7/17/2020 (nms). (Entered: 07/17/2020) (2) |
| Jul 2, 2020 | 141 | ORDER Granting 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss. Signed by Judge Richard G. Andrews on 7/2/2020. (nms) (Entered: 07/02/2020) (1) |
| Jul 2, 2020 | 142 | [SEALED] ANSWERING BRIEF in Opposition re 71 MOTION to Dismiss, filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(nms) (Entered: 07/02/2020) (0) |
| Jul 2, 2020 | 143 | REDACTED VERSION of 142 Answering Brief in Opposition by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(DiGiovanni, Francis) (Entered: 07/02/2020) (Main Document) (23) |
| Jul 2, 2020 | 143 | REDACTED VERSION of 142 Answering Brief in Opposition by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(DiGiovanni, Francis) (Entered: 07/02/2020) (Exhibit 1) (1) |
| Jul 2, 2020 | 143 | REDACTED VERSION of 142 Answering Brief in Opposition by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(DiGiovanni, Francis) (Entered: 07/02/2020) (Exhibit 2) (1) |
| Jul 1, 2020 | 138 | [SEALED] EXHIBITS re 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(DiGiovanni, Francis) Modified on 7/1/2020 (nms). (Main Document 138 replaced on 7/2/2020) (nms). (Entered: 07/01/2020) (0) |
| Jul 1, 2020 | 139 | DECLARATION re 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1 (to Ex. A), # 3 Exhibit 2 (to Ex. A))(DiGiovanni, Francis) (Entered: 07/01/2020) (Main Document) (2) |
| Jul 1, 2020 | 140 | STIPULATION for Extension of Time - filed by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 7/2/2020 (nms). (Entered: 07/01/2020) (2) |
| Jul 1, 2020 | 139 | DECLARATION re 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1 (to Ex. A), # 3 Exhibit 2 (to Ex. A))(DiGiovanni, Francis) (Entered: 07/01/2020) (Exhibit A) (24) |
| Jul 1, 2020 | 139 | DECLARATION re 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1 (to Ex. A), # 3 Exhibit 2 (to Ex. A))(DiGiovanni, Francis) (Entered: 07/01/2020) (Exhibit 1 (to Ex. A)) (1) |
| Jul 1, 2020 | 139 | DECLARATION re 137 MOTION to File Under Seal Answering Brief to Motion to Dismiss by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit 1 (to Ex. A), # 3 Exhibit 2 (to Ex. A))(DiGiovanni, Francis) (Entered: 07/01/2020) (Exhibit 2 (to Ex. A)) (1) |
| Jun 30, 2020 | 137 | MOTION to File Under Seal Answering Brief to Motion to Dismiss - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 7/1/2020 (nms). (Entered: 06/30/2020) (4) |
| May 21, 2020 | 136 | STIPULATION and Proposed Order for Extension of Due Date - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 5/21/2020 (nms). (Entered: 05/21/2020) (2) |
| Apr 21, 2020 | 135 | STIPULATION TO EXTEND TIME To File Answering Brief to Mylan's Motion to Dismiss (D.I. 71) to June 1, 2020 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 04/21/2020) (2) |
| Mar 26, 2020 | 134 | STIPULATION TO EXTEND TIME to file its Answering Brief to April 30, 2020 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 03/26/2020) (2) |
| Mar 24, 2020 | 133 | CORRECTED ORDER of USCA as to 115 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc., and 118 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc.. Decision of USCA: The motion for an injunction pending appeal is denied, and the interim injunction granted in the court's January 29, 2020 order is lifted. Mylan's motion to modify the court's January 29, 2020 order is denied. (nms) (Entered: 03/24/2020) (4) |
| Mar 23, 2020 | 132 | ORDER of USCA as to 115 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc., and 118 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc.. Decision of USCA: The motion for an injunction pending appeal is denied, and the interim injunction granted in the court's January 29, 2020 order is lifted. Mylan's motion to modify the court's January 29, 2020 order is denied. (nms) (Entered: 03/23/2020) (4) |
| Mar 11, 2020 | 131 | STIPULATION TO EXTEND TIME To File Answering Brief to Mylan's Motion to Dismiss to March 31, 2020 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 03/11/2020) (2) |
| Feb 28, 2020 | 130 | STIPULATION and Proposed Order for Extension of Due Date - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 2/28/2020 (nms). (Entered: 02/28/2020) (2) |
| Feb 13, 2020 | 129 | STIPULATION TO EXTEND TIME to file its Answering Brief to March 3, 2020 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 02/13/2020) (2) |
| Feb 12, 2020 | 128 | TRANSCRIPT REQUEST by Takeda Pharmaceuticals U.S.A., Inc. for proceedings held on January 21, 2020 before Judge Richard G. Andrews. (Rahmeier, Thatcher) (Entered: 02/12/2020) (1) |
| Feb 4, 2020 | 126 | Official Transcript of Oral Argument held on 01/21/20 before Judge Richard G. Andrews. Court Reporter/Transcriber Stacy Ingram,Email: Stacy.ingram1@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/25/2020. Redacted Transcript Deadline set for 3/6/2020. Release of Transcript Restriction set for 5/4/2020. (Triozzi, Heather) (Entered: 02/04/2020) (101) |
| Feb 4, 2020 | 127 | REDACTED VERSION of 105 Exhibits to Motion to Seal, by Mylan Pharmaceuticals Inc.. (Dorsney, Kenneth) Modified on 2/5/2020 (nms). (Entered: 02/04/2020) (19) |
| Feb 3, 2020 | 125 | NOTICE of Firm Name Change and E-Mail Contact Change by Takeda Pharmaceuticals U.S.A., Inc. (DiGiovanni, Francis) (Entered: 02/03/2020) (2) |
| Jan 31, 2020 | 123 | STIPULATION TO EXTEND TIME to file its Answering Brief to February 18, 2020 - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 01/31/2020) (2) |
| Jan 31, 2020 | 124 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 118 Amended Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc.. USCA Case Number 2020-1417. (nms) (Entered: 01/31/2020) (3) |
| Jan 29, 2020 | 119 | TRANSCRIPT REQUEST by Takeda Pharmaceuticals U.S.A., Inc. for proceedings held on January 21, 2020 before Judge Richard G. Andrews. (Rahmeier, Thatcher) (Entered: 01/29/2020) (1) |
| Jan 29, 2020 | 120 | NOTICE of Withdrawal of Motion to Seal by Mylan Pharmaceuticals Inc. re 104 MOTION to File Under Seal and Response to Motion to File Under Seal, 105 Exhibit to a Document (Dorsney, Kenneth) (Entered: 01/29/2020) (2) |
| Jan 29, 2020 | 121 | ORDER of USCA as to 118 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals U.S.A., Inc.. Decision of USCA on Motion: Mylan is directed to respond to the motion for an injunction pending appeal no later than seven days from the date of filing of this order. Any reply in support of the motion is due no later than three days thereafter. Takeda's request for an interim injunction is granted to the extent that the district court's order that Mylan "maintain the status quo" shall remain in effect pending the court's consideration of Takeda's request for an injunction pending appeal. (nms) (Entered: 01/29/2020) (2) |
| Jan 29, 2020 | 122 | REDACTED VERSION of 87 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) Modified on 1/30/2020 (nms). (Entered: 01/29/2020) (Main Document) (4) |
| Jan 29, 2020 | 122 | REDACTED VERSION of 87 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) Modified on 1/30/2020 (nms). (Entered: 01/29/2020) (Exhibit A) (15) |
| Jan 29, 2020 | 122 | REDACTED VERSION of 87 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) Modified on 1/30/2020 (nms). (Entered: 01/29/2020) (Exhibit B) (15) |
| Jan 29, 2020 | 122 | REDACTED VERSION of 87 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) Modified on 1/30/2020 (nms). (Entered: 01/29/2020) (Exhibit C) (4) |
| Jan 29, 2020 | 122 | REDACTED VERSION of 87 Declaration, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiGiovanni, Francis) Modified on 1/30/2020 (nms). (Entered: 01/29/2020) (Exhibit D) (4) |
| Jan 28, 2020 | 118 | Notice of Appeal* (1) |
| Jan 27, 2020 | 115 | Notice of Appeal* (1) |
| Dec 11, 2019 | 20 | Complaint* (1) |
